Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Consensus PT from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given an average recommendation of “Buy” by the six ratings firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $21.00.

ARTV has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. HC Wainwright initiated coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 price target on the stock.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics in the third quarter worth approximately $42,000. MetLife Investment Management LLC bought a new stake in Artiva Biotherapeutics during the third quarter valued at about $135,000. JPMorgan Chase & Co. purchased a new position in Artiva Biotherapeutics in the third quarter valued at about $166,000. Barclays PLC bought a new position in Artiva Biotherapeutics in the third quarter worth about $304,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Artiva Biotherapeutics during the third quarter valued at about $623,000.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $10.67 on Monday. Artiva Biotherapeutics has a twelve month low of $9.68 and a twelve month high of $17.31. The business has a 50-day simple moving average of $11.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, equities analysts forecast that Artiva Biotherapeutics will post -4.68 earnings per share for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.